Johnson & Johnson says Phase 3 Vivacity-MG3 analyses show IMAAVY sustains symptom control in generalized myasthenia gravis

Johnson & Johnson

Johnson & Johnson

JNJ

0.00
  • Johnson & Johnson flagged new Phase 3 Vivacity-MG3 analyses on IMAAVY for generalized myasthenia gravis, slated for presentation at EAN 2026.
  • The updated readouts indicate sustained symptom control and daily-function improvements versus placebo across key patient subgroups, including earlier-stage disease.
  • Separate analyses suggest patients maintained disease control following common infections, a frequent trigger for worsening symptoms.
  • Safety trends remained broadly consistent with prior nipocalimab studies, with similar overall adverse-event rates versus placebo and fewer serious events.
  • J&J also plans to present the PETUNIA pregnancy-outcomes study design to generate post-marketing real-world safety data for IMAAVY exposure during pregnancy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606261235PR_NEWS_USPR_____NY92690) on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.